ArticleKidney international2014
Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease.
Article in Kidney international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Endothelin receptor antagonists in chronic kidney disease.Nature reviews. Nephrology · 2025Review
- Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- In Patients With Hypertension, the Cortical Perfusion Index Measured by Contrast Enhanced Ultrasound Reveals a Sexual Dimorphism.Journal of the American Heart Association · 2025Article
- Epigenetics of Hypertensive Nephropathy.Biomedicines · 2024Review
- With a Little Help From My Friends: the Role of the Renal Collateral Circulation in Atherosclerotic Renovascular Disease.Hypertension (Dallas, Tex. : 1979) · 2022Review
- Microvascular dysfunction and kidney disease: Challenges and opportunities?Microcirculation (New York, N.Y. : 1994) · 2021Review
- Peritubular Capillary Rarefaction: An Underappreciated Regulator of CKD Progression.International journal of molecular sciences · 2020Review
- A Boolean Model of Microvascular Rarefaction to Predict Treatment Outcomes in Renal Disease.Scientific reports · 2020Article
- Recovery of Renal Function following Kidney-Specific VEGF Therapy in Experimental Renovascular Disease.American journal of nephrology · 2020Article
- Biopolymer-delivered vascular endothelial growth factor improves renal outcomes following revascularization.American journal of physiology. Renal physiology · 2019Article
- A dual blocker of endothelin A/B receptors mitigates hypertension but not renal dysfunction in a rat model of chronic kidney disease and sleep apnea.American journal of physiology. Renal physiology · 2019Article
- Small Vessels, Big Role: Renal Microcirculation and Progression of Renal Injury.Hypertension (Dallas, Tex. : 1979) · 2017Review
- Renal Therapeutic Angiogenesis Using a Bioengineered Polymer-Stabilized Vascular Endothelial Growth Factor Construct.Journal of the American Society of Nephrology : JASN · 2016Article
- Vascular Endothelial Growth Factor and Podocyte Protection in Chronic Hypoxia: Effects of Endothelin-A Receptor Antagonism.American journal of nephrology · 2016Article
- Endothelin-1 and the kidney: new perspectives and recent findings.Current opinion in nephrology and hypertension · 2016Review
- Vascular Endothelial Growth Factor Therapy for the Kidney: Are We There Yet?Journal of the American Society of Nephrology : JASN · 2016Article
- Gained in translation: protective paradigms for the poststenotic kidney.Hypertension (Dallas, Tex. : 1979) · 2015Review
- Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease.Journal of the American Society of Nephrology : JASN · 2015Article
- Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015Article
- Endothelin and the glomerulus in chronic kidney disease.Seminars in nephrology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
We hypothesized that chronic specific endothelin-A (ET-A) receptor blockade therapy would reverse renal dysfunction and injury in advanced experimental renovascular disease. To test this, unilateral renovascular disease was induced in 19 pigs, and after 6 weeks, single-kidney hemodynamics and function was quantified in vivo using computed tomography. All pigs with renovascular disease were divided such that seven were untreated, seven were treated with ET-A blockers, and five were treated with ET-B blockers. Four weeks later, all pigs were restudied in vivo, and then killed and ex vivo studies performed on the stenotic kidney to quantify microvascular density, remodeling, renal oxidative stress, inflammation, and fibrosis. Renal blood flow, glomerular filtration rate, and redox status were significantly improved in the stenotic kidney after ET-A but not ET-B blockade. Furthermore, only ET-A blockade therapy reversed renal microvascular rarefaction and diminished remodeling, which was accompanied by a marked decreased in renal inflammatory and fibrogenic activity. Thus, ET-A but not ET-B blockade ameliorated renal injury in pigs with advanced renovascular disease by stimulating microvascular proliferation and decreasing the progression of microvascular remodeling, renal inflammation, and fibrosis in the stenotic kidney. These effects were functionally consequential as ET-A blockade improved single kidney microvascular endothelial function, renal blood flow, and glomerular filtration rate, and decreased albuminuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.